XML 33 R20.htm IDEA: XBRL DOCUMENT
v3.10.0.1

Acquisition, Restructuring and Other Expense | 12 Months Ended
--- | ---
Dec. 31, 2018
Acquisition, Restructuring Expenses and Other Operating Expenses [Abstract] |
Acquisition, Restructuring and Other Expense | Acquisition, Restructuring and Other Expense Acquisition, restructuring and other expense for the year ended December 31, consists of the following:
| 2018 |  | 2017 |  | 2016
Consolidation costs | $ | — |  |  | $ | 2,903 |  |  | $ | 3,066 |
Termination of a product offering | — |  |  | — |  |  | 4,546 |
Restructuring costs included in cost of sales | $ | — |  |  | $ | 2,903 |  |  | $ | 7,612 |
Business acquisition costs | $ | 2,372 |  |  | $ | 2,336 |  |  | $ | 17,029 |
Restructuring costs | — |  |  | 1,347 |  |  | 6,670 |
Legal matters | — |  |  | 17,480 |  |  | 3,773 |
Gain on sale of facility | — |  |  | — |  |  | (1,890 | )
Acquisition, restructuring and other expense included in selling and administrative expense | $ | 2,372 |  |  | $ | 21,163 |  |  | $ | 25,582 |
Impairment charges included in research and development expense | $ | 4,212 |  |  | $ | — |  |  | $ | — |
Debt refinancing costs included in other expense | $ | — |  |  | $ | — |  |  | $ | 2,942 |
During 2018, 2017 and 2016 we incurred $1.1 million, $2.3 million and $17.0 million respectively, in costs associated with the January 4, 2016 acquisition of SurgiQuest, Inc. as further described in Note 2. The costs incurred in 2018 consist of a charge to selling and administrative expense associated with a vacant lease related to the acquisition. The costs incurred in 2017 consist of costs associated with expensing of unvested options acquired and integration related costs. The costs incurred in 2016 consist of investment banking fees, consulting fees, legal fees associated with the acquisition, costs associated with expensing of unvested options acquired and integration related costs. During 2018, we incurred $1.3 million in consulting, legal and other costs associated with the February 11, 2019 acquisition of Buffalo Filter as further described in Note 17. During 2018, we recorded a net charge of $4.2 million to research and development expense mainly associated with the impairment of an in-process research and development asset, net of the release of previously accrued contingent consideration in other current and long-term liabilities, as further described in Note 12. During 2017, we incurred $12.2 million in costs associated with the SurgiQuest, Inc. vs. Lexion Medical litigation verdict whereby SurgiQuest was found liable for $2.2 million in compensatory damages with an additional $10.0 million in punitive damages as further described in Note 12. These costs were paid on July 10, 2018. In addition, during the years ended December 31, 2017 and 2016, we incurred $5.3 million and $3.8 million, respectively, in costs associated with this litigation and other legal matters. During 2016, we incurred a $2.7 million charge related to commitment fees paid to certain of our lenders, which provided a financing commitment for the SurgiQuest acquisition and recorded a loss on the early extinguishment of debt of $0.3 million in conjunction with the fifth amended and restated senior credit agreement as further described in Note 6. For the years ending December 31, 2017 and 2016, we incurred $2.9 million and $3.1 million, respectively, in costs associated with operational restructuring. These costs were charged to cost of sales and included severance, inventory and other charges. As part of this plan, we engaged a consulting firm to assist us in streamlining our product offering and improving our operational efficiency. As a result, we identified certain catalog numbers to be discontinued and consolidated into existing product offerings and recorded a $1.3 million charge in the year ended December 31, 2017 to write-off inventory which will no longer be offered for sale. This amount is included in the above total for 2017. During 2016, we discontinued our Altrus product offering as part of our ongoing restructuring and incurred $4.5 million in non-cash charges primarily related to inventory and fixed assets which were included in cost of sales during 2016. During 2016, we sold our Centennial, Colorado facility. We received net cash proceeds of $5.2 million and recorded a gain of $1.9 million on the sale. During 2017 and 2016, we restructured certain selling and administrative functions and incurred $1.3 million and $6.7 million, respectively, in related costs consisting principally of severance charges.

X
- Definition Acquisition, Restructuring Expense and Other Operating Expense [Text Block] + References No definition available. + Details
Name: | cnmd_AcquisitionRestructuringExpenseandOtherOperatingExpenseTextBlock
Namespace Prefix: | cnmd_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Acquisition, Restructuring Expenses and Other Operating Expenses [Abstract] + References No definition available. + Details
Name: | cnmd_AcquisitionRestructuringExpensesandOtherOperatingExpensesAbstract
Namespace Prefix: | cnmd_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration